Clinical Trial Update: A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating how PF-06821497 (Mevrometostat) works in men with metastatic castration-resistant prostate cancer; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• PF-06821497 (Mevrometostat) (Mevrometostat)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Status: RECRUITING